A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations

Smoliga, James M.; Colombo, E.; Campen, Matthew J.

doi:10.18632/aging.100579

Cited by 36 publications

(38 citation statements)

References 79 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, results obtained from clinical trials in humans evaluating the potential effects of resveratrol have generated considerable controversy, and in some cases the findings of these trials are not consistent with results from animal models (Yoshino et al, 2012;Smoliga et al, 2013). However, disparity in dosing protocols and clinical paradigms may cause conflicting findings.…”

Section: Resveratrolmentioning

confidence: 99%

See 1 more Smart Citation

Caloric restriction, resveratrol and melatonin: Role of SIRT1 and implications for aging and related-diseases

Ramis

Esteban

Miralles

et al. 2015

Mechanisms of Ageing and Development

125

View full text Add to dashboard Buy / Rent full text

Section: Resveratrolmentioning

confidence: 99%

“…However, disparity in dosing protocols and clinical paradigms may cause conflicting findings. Only long-term epidemiological studies and meta-analysis can clarify the use of resveratrol as a therapy to reduce the physiological decline and age-related diseases (Smoliga et al, 2013).…”

Section: Resveratrolmentioning

confidence: 99%

Caloric restriction, resveratrol and melatonin: Role of SIRT1 and implications for aging and related-diseases

Ramis

Esteban

Miralles

et al. 2015

Mechanisms of Ageing and Development

125

View full text Add to dashboard Buy / Rent full text

“…Major inflammatory biomarkers such as CRP are clearly elevated by acute cardiovascular events and have some value in predicting risk or reclassification [41], but common therapies and medications may affect CRP levels and nullify the predictive power [42]. Moreover, elevations of one inflammatory factor my be offset by an anti-inflammatory factor, which motivated the development of the SCIP assay as an unbiased means of addressing how a pathology-relevant cell type, such as endothelial cells, interpret the gestalt balance of circulating pro- and anti-inflammatory factors [43]. This assay has proven valuable for both studies of therapeutic benefit [24] and environmental health outcomes [44], as well as highlighting inflammatory differences between coronary artery disease patients and controls even after months of standard of care pharmacotherapy [23].…”

Section: Discussionmentioning

confidence: 99%

Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells

et al. 2016

Self Cite

View full text Add to dashboard Buy / Rent full text

Background and aims Obstructive sleep apnea (OSA) is characterized by intermittent airway obstruction and systemic hypoxia during sleep, which can contribute to an increase in reactive oxygen species, vascular remodeling, vasoconstriction and ultimately cardiovascular disease. Continuous positive airway pressure (CPAP) is a clinical therapy that maintains airway patency and mitigates several symptoms of OSA. However, it is currently unknown whether CPAP therapy also reduces the overall inflammatory potential in the circulation; to address this in an unbiased manner, we applied a novel endothelial biosensor approach, the serum cumulative inflammatory potential (SCIP) assay. Methods We studied healthy controls (n=7), OSA subjects receiving no treatment, (OSA controls) (n=7) and OSA subjects receiving CPAP for 3 months (n=8). Serum was obtained from OSA subjects before and after CPAP or no treatment. A battery of quantitative and functional assays was performed to assess the serum inflammatory potential, in terms of endothelial responses. For the SCIP assay, human coronary artery endothelial cells (hCAECs) were incubated with 5% serum in media from individual subjects for 4 h. qPCR was performed to assess endothelial inflammatory transcript (ICAM-1, VCAM-1, IL-8, P-selectin, CCL5, and CXCL12) responses to serum. Additionally, transendothelial resistance was measured in serum-incubated hCAECs following leukocyte challenge. Results hCAECs exhibited significant increases in VCAM-1, ICAM-1, IL-8 and P-selectin mRNA when incubated with serum from OSA patients compared to serum from healthy control subjects. Furthermore, compared to no treatment, serum from CPAP-treated individuals was less potent at inducing inflammatory gene expression in the SCIP assay. Similarly, in a leukocyte adhesion assay, naïve cells treated with serum from patients who received CPAP exhibited improved endothelial barrier function than cells treated with OSA control serum. Conclusions OSA results in greater serum inflammatory potential, thereby driving endothelial activation and dysfunction.

show abstract

“…Yet, there is no clinical justification to treat those subjects or expect such effects. Moreover, it is not clear how positive effects in an already healthy population should be interpreted (Smoliga et al, 2013). On the other hand, enough evidence has been gathered to suggest that compromised populations such as the elderly do benefit from treatment with RV (Smoliga et al, 2013).…”

Section: Perspectivementioning

confidence: 99%

“…Moreover, it is not clear how positive effects in an already healthy population should be interpreted (Smoliga et al, 2013). On the other hand, enough evidence has been gathered to suggest that compromised populations such as the elderly do benefit from treatment with RV (Smoliga et al, 2013). Even though a recent series of publications in aged humans (Gliemann et al, 2014(Gliemann et al, , 2013Olesen et al, 2014b) reveals no benefit from RV supplementation in a broad range of cardiovascular and metabolic parameters, further research needs to be conducted to definitely validate the claims both in favor and against RV.…”

Section: Perspectivementioning

confidence: 99%

The effects of resveratrol on aging vessels

Diaz

Degens

Vanhees

et al. 2016

Experimental Gerontology

View full text Add to dashboard Buy / Rent full text

Aging is a major risk factor for the development of cardiovascular disease. Despite a significant reduction in the mortality and morbidity rates over the last decade, the socio-economic burden of cardiovascular disease is still substantial. Consequently, there is a considerable need for alternative strategies, such as nutraceutical supplementation, that delay the functional vascular decline present in the elderly.Compromised autophagy and oxidative stress (OS) are considered major causes of the age-related endothelial dysfunction. OS reduces the bioavailability of nitric oxide (NO), which has been associated with hypertension, arteriosclerosis and a reduced vasodilatory response. High levels of free radicals and the low bioavailability of NO lead to a positive feedback loop of further OS, organelle damage, poor repair and endothelial dysfunction. Here we draw attention to the relationship between OS and autophagy in the aged vasculature. We have reviewed the published literature and provided arguments that support that treatment with resveratrol stimulates autophagy and thereby has the potential to restore oxidative balance in the endothelium, which indicates that treatment with resveratrol might have therapeutic potential to restore endothelial function in the elderly.

show abstract

A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations

Cited by 36 publications

References 79 publications

Caloric restriction, resveratrol and melatonin: Role of SIRT1 and implications for aging and related-diseases

Caloric restriction, resveratrol and melatonin: Role of SIRT1 and implications for aging and related-diseases

Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells

The effects of resveratrol on aging vessels

Contact Info

Product

Resources

About